Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotypes of schizophrenia.

1. Schizophrenia (Heidelb). 2024 May 30;10(1):55. doi: 10.1038/s41537-024-00474-0.

Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotypes of schizophrenia.

Gao Z(1), Guo X(1), Sun Z(1), Wu S(1), Wang Q(1), Huang Q(1), Bai W(2), Kou C(3).

Author information: (1)Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin, China. (2)Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin, China. baiweijlu@jlu.edu.cn. (3)Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin, China. koucg@jlu.edu.cn.

Phospholipase A2(PLA2) superfamily is recognized as being involved in the pathogenesis of schizophrenia by affecting lipid homeostasis in cell membranes. We hypothesized that PLA2 gene copy number variation (CNV) may affect PLA2 enzyme expression and be associated with schizophrenia risk. This study indicated that in the discovery stage, an increased copy number of PLA2G6 and the deletion of PLA2G3, PLA2G4A, PLA2G4F and PLA2G12F was associated with increased risk of schizophrenia. CNV segments involving six PLA2 genes were detected in publicly available datasets, including two deletion segments specific to the PLA2G4A gene. The relationship between the deletion of PLA2G4A and susceptibility to schizophrenia was then reaffirmed in the validation group of 806 individuals. There was a significant correlation between PLA2G4A deletion and the symptoms of poverty of thought in male patients and erotomanic delusion in females. Furthermore, ELISA results demonstrate a significant decrease in peripheral blood cytosolic PLA2(cPLA2) levels in patients with the PLA2G4A deletion genotype compared to those with normal and copy number duplicate genotypes. These data suggest that the functional copy number deletion in the PLA2G4A gene is associated with the risk of schizophrenia and clinical phenotypes by reducing the expression of cPLA2, which may be an indicator of susceptibility to schizophrenia.

© 2024. The Author(s).

DOI: 10.1038/s41537-024-00474-0 PMCID: PMC11139948 PMID: 38816399

Conflict of interest statement: The authors declare no competing interests.